Streetbeat News

Products Services

LTRN

Lantern Pharma Inc. (NASDAQ:LTRN) has announced the publication of in vivo data highlighting the enhanced efficacy of its drug candidate LP-184 in glioblastoma (GBM) in Clinical Cancer Research. LP-184 is a unique small molecule that exploits common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. A Phase 1 clinical trial evaluating LP-184 in patients with advanced solid tumors is underway, with completion expected in the first half of 2024. Lantern estimates that LP-184 has a global aggregate market potential of approximately $11-13 billion.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:11 pm

URGN

UroGen Pharma has announced that it will begin the rolling NDA submission for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, in January 2024. This follows a pre-NDA meeting with the FDA.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:10 pm

NVO

Novo Nordisk Foundation CEO has expressed surprise at the successful launch of the weight-loss drug Wegovy. He hopes that Novo Nordisk will be able to replenish its pipeline after Semaglutide, indicating confidence in the company's long-term strategy.

Portfolio Pulse from Charles Gross

October 03, 2023 | 12:10 pm

V

Visa Inc. has announced a $100 million initiative to foster the development of generative AI technologies and applications. The initiative, led by Visa Ventures, will invest in companies developing these technologies, which are expected to revolutionize content creation and task execution. Visa has also launched the Visa Ready to Launch (VRTL) program to address challenges faced by fintechs and non-banking entities.

Portfolio Pulse from Nabaparna Bhattacharya

October 03, 2023 | 12:09 pm

MSTR

MicroStrategy has announced the launch of MicroStrategy AI, a new addition to its AI/BI platform. This new product allows organizations to integrate AI experiences into their applications and products, all based on trusted data.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:08 pm

MSTR

MicroStrategy Incorporated (NASDAQ:MSTR) has unveiled MicroStrategy AI, a product that allows organizations to incorporate generative AI into their data applications. The integration simplifies data analysis and interaction with data insights, making it more accessible.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:07 pm

AYRO

AYRO, a US-based electric vehicle manufacturer, has been granted a patent for its user-tailored vehicle seat fabrication technology. This technology allows for customization of vehicle seats based on user preferences, potentially enhancing the user experience and giving AYRO a competitive edge in the EV market.

Portfolio Pulse from Bill Haddad

October 03, 2023 | 12:07 pm

AZN

OCEA

Ocean Biomedical has published findings demonstrating its ability to restore treatment sensitivity to AstraZeneca's Tagrisso after resistance has formed, and improved tumor suppression in EGFR-Mutation Lung Cancers.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:04 pm

MAIA

MAIA Biotechnology has announced that the FDA has cleared its Investigational New Drug (IND) application for THIO, a first-in-class telomere targeting agent for treating non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:03 pm

GALT

Galectin Therapeutics, Inc. (NASDAQ:GALT) reported a positive outcome from its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, a Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. The study is a global effort that randomized 357 patients in 14 countries. Interim topline data from the Phase 2b portion of NAVIGATE is expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:03 pm